Here's what you need to know:
1. TRS' 3D printing methods will improve DePuy Synthes' ability to create patient-specific bioresorbable implants with a unique mineral coating.
2. The implants support bone healing in patients with orthopedic and craniomaxillofacial deformities and injuries.
3. The acquisition is expected to help DePuy's trauma platform thrive.
4. Johnson & Johnson, DePuy Synthes' parent company, hopes to develop more patient-specific healthcare solutions with 3D printing technology.
5. DePuy and TRS began collaborating in 2014 through Johnson & Johnson Innovation.
Johnson & Johnson Global Head Robert G. Urban, PhD, said, "The acquisition of the TRS technology by DePuy Synthes is testament to our ability to identify and work collaboratively with promising early-stage companies and entrepreneurs to accelerate bringing innovative new products to market."
More articles on devices:
MIS, outpatient spine, robotics & more — Centers for Advanced Orthopaedics' surgeons talk technology